Drug Guidance for Subsidy 01/10/2018 Lanthanum carbonate and sevelamer carbonate for treating hyperphosphataemia in patients with chronic kidney disease The Ministry of Health’s Drug Advisory Committee has recommended: Sevelamer carbonate 800 mg... See all × 01/10/2018 Lanthanum carbonate and sevelamer carbonate for treating hyperphosphataemia in patients with chronic kidney disease The Ministry of Health’s Drug Advisory Committee has recommended: Sevelamer carbonate 800 mg tablet for the treatment of hyperphosphataemia in patients with chronic kidney disease who: have persistent hyperphosphataemia despite optimising treatment with calcium-based phosphate binders; or cannot tolerate calcium-based phosphate binders due to hypercalcaemia. Subsidy status RSevelamer carbonate 800 mg tablet is recommended for inclusion on the Medication Assistance Fund (MAF) for the abovementioned indication. NRMAF assistance does not apply to lanthanum carbonate 500 mg, 750 mg, and 1000 mg tablets.
General Availability in Public Healthcare Institution Users are to consult the respective PHIs for actual inventory availability and supply restrictions/consideration Tablet, Chewable 500 mg Alexandra Hospital Changi General Hospital Khoo Teck Puat Hospital Ng Teng Fong General Hospital National University Hospital Singapore General Hospital Tan Tock Seng Hospital Woodlands Health Campus Tablet, Chewable 1,000 mg Alexandra Hospital Khoo Teck Puat Hospital Ng Teng Fong General Hospital National University Hospital Sengkang General Hospital Singapore General Hospital Tan Tock Seng Hospital Woodlands Health Campus
ORAL Select a brand starting with the letter: F FOSRENOL CHEWABLE TABLETS 1000MG [SIN13596P] FOSRENOL CHEWABLE TABLETS 500MG [SIN13594P]